|
|
EP67 |
|
Vaxjo ID |
488 |
|
Vaccine Adjuvant Name |
EP67 |
|
Adjuvant VO ID |
VO_0005765
|
|
Description |
peptide vaccine adjuvant that induces Th1/Th2 balanced response |
|
Stage of Development |
Research |
|
Location Licensed |
United States |
|
Host Species for Testing |
Mouse |
|
Components |
YSFKDMP(MeL)aR |
|
Preparation |
synthesized by standard Fmoc (9-fluoreny-lmethoxy-carbonyl) solid-phase methods on a pre-loaded Arg Wang resin by sequential coupling of the HBTU (2-(1H-benzotriazole-1-yl-1,1,3,3-tetramethyluronium hexafluoro-phosphate) esters of each amino acid |
|
Function |
Type: peptide vaccine adjuvant. Induces Th1-biased immune profile. EP67 focuses the Ag on APCs, via binding to CD88, resulting in improved Ag presentation and in addition induces these cells to provide accessory stimulatory signals that further enhance immune function |
| References |
Morgan et al., 2009: Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, Sanderson SD, Phillips JA. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine. 2009; 28(2); 463-469. [PubMed: 19836478].
|
|
